Three-fourths of patients had cancer-free mediastinal lymph nodes, clear surgical margins ...

Neoadjuvant immunotherapy is expanding treatment options in CSCC by shrinking complex tumors, improving surgical outcomes, ...

The extent of residual prostate cancer in the surgical specimen following intensified neoadjuvant therapy for high-risk localized prostate cancer may predict metastatic recurrence. Residual disease ...

There’s an ongoing uncertainty among experts about whether neoadjuvant therapy or surgery first is best for patients with ...

Oncologists are increasingly reaching for the prescription pad before the scalpel, driving a dramatic rise in the use of neoadjuvant therapy for solid tumors, according to new research. The second ...

Neoadjuvant Therapy for Locally Advanced Rectal Cancer: Omission of Radiotherapy or Not? The following represents disclosure information provided by authors of this manuscript. All relationships are ...

Tissue-Free Circulating Tumor DNA Assay and Patient Outcome in a Phase III Trial of FOLFOX-Based Adjuvant Chemotherapy (Alliance N0147) Neoadjuvant approaches for HER2-positive breast cancer continue ...

TNT achieved a 93.7% complete response rate and 87.5% organ preservation in stage I rectal cancer patients. TNT may offer an organ-preserving alternative to surgery, especially for low-lying tumors, ...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced the successful presentation of clinical data at the American Association for Cancer Research ...